18 May 2020 13:34
The information contained within this announcement is considered by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No.596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information will be considered to be in the public domain.
Cathay International Holdings Limited
("Cathay" or the "Company")
Director/PDMR Shareholding
Hong Kong, 18 May 2020 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China announces, as required by Article 19 Of Regulation (EU) No. 596/2014 on market abuse, that Mr. Wu Zhen Tao participated in the Open Offer through Circle Finance Limited and Mega Worldwide Services Limited, in respect of an aggregate of 1,148,784,403 Open Offer Shares and 2,916,256,247 Convertible Instruments：.
Director | Number of Common Shares held prior to the Open Offer and Subscription | % of Common Share prior to the Open Offer and Subscription | Open Offer Shares | Number of Common shares held following the Open Offer and Subscription | % of Common Shares following the Open Offer and Subscription | Convertible Instruments held following the Open Offer and Subscription |
Wu Zhen Tao | 225,156,434(1) | 59.5% | 1,148,784,403 | 1,373,940,837 (1) | 71.79% | 2,916,256,247 |
(1) held through Circle Finance Limited and Mega Worldwide Services Limited.
The notification below provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
DMR DEALING NOTIFICATION TEMPLATE | |||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Wu Zhen Tao | |
2 | Reason for the notification | ||
a) | Position/status | Non-Executive Chairman | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Cathay International Holdings Limited | |
b) | Legal Entity Identifier | 2138008QE2WNVHSYYO80 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | USD 0.01 per Common Share | |
Identification code | LSE:CTI | ||
b) | Nature of the transaction | Purchase of New Ordinary Shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
1.5 pence | 1,148,784,403
| ||
d) | Aggregated information |
Not applicable - single transaction
| |
- Aggregated volume | |||
- Price | |||
e) | Date of the transaction | 18 May 2020 | |
f) | Place of the transaction |
London Stock Exchange | |
- ENDS -
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Patrick Sung (Director and Controller)
|
Tel: +852 2828 9289 |
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 1,300 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.